メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血液減少症:世界の治験動向

Hypovolemia (Hypovolaemia) Global Clinical Trials Review, H2, 2017

発行 GlobalData 商品コード 344250
出版日 ページ情報 英文 47 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.61円で換算しております。
Back to Top
血液減少症:世界の治験動向 Hypovolemia (Hypovolaemia) Global Clinical Trials Review, H2, 2017
出版日: 2017年10月31日 ページ情報: 英文 47 Pages
概要

当レポートでは、血液減少症の治験に関する最新動向について分析しており、各地域の主要国における治験件数、治験の段階別進行状況、被験者採用の状況、有望なスポンサー、各企業や研究機関における研究の進行状況、有望な薬剤の比較といった情報をまとめています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:血液疾患治療薬の治験における血液減少症の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:血液疾患治療薬の治験における血液減少症の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

血液減少症治療薬の治験に携わっている主要企業

有望な薬剤

治験プロファイルの概要

付録

目次
Product Code: GDHC4638CTIDB

GlobalData's clinical trial report, "Hypovolemia (Hypovolaemia) Global Clinical Trials Review, H2, 2017" provides an overview of Hypovolemia (Hypovolaemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Hypovolemia (Hypovolaemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 3
  • Report Guidance 4
  • GlobalData Clinical Trials Report Coverage 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Clinical Trials by G7 Countries: Proportion of Hypovolemia (Hypovolaemia) to Metabolic Disorders Clinical Trials 13
  • Clinical Trials by Phase in G7 Countries 14
  • Clinical Trials in G7 Countries by Trial Status 15
  • Clinical Trials by E7 Countries: Proportion of Hypovolemia (Hypovolaemia) to Metabolic Disorders Clinical Trials 16
  • Clinical Trials by Phase in E7 Countries 17
  • Clinical Trials by Phase 18
  • In Progress Trials by Phase 19
  • Clinical Trials by Trial Status 20
  • Clinical Trials by End Point Status 21
  • Subjects Recruited Over a Period of Time 22
  • Clinical Trials by Sponsor Type 23
  • Prominent Sponsors 24
  • Top Companies Participating in Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials 26
  • Prominent Drugs 28
  • Clinical Trial Profile Snapshots 29

Appendix 45

  • Abbreviations 45
  • Definitions 45
  • Research Methodology 46
  • Secondary Research 46
  • About GlobalData 47
  • Contact Us 47
  • Source 47

List of Tables

List of Tables

  • Hypovolemia (Hypovolaemia) Therapeutics, Global, Clinical Trials by Region, 2017* 6
  • Hypovolemia (Hypovolaemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Hypovolemia (Hypovolaemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 9
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 10
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, North America, Top Countries, 2017* 11
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 12
  • Proportion of Hypovolemia (Hypovolaemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 13
  • Hypovolemia (Hypovolaemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
  • Hypovolemia (Hypovolaemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 15
  • Proportion of Hypovolemia (Hypovolaemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 16
  • Hypovolemia (Hypovolaemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 17
  • Hypovolemia (Hypovolaemia) Therapeutics, Global, Clinical Trials by Phase, 2017* 18
  • Hypovolemia (Hypovolaemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 19
  • Hypovolemia (Hypovolaemia) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 20
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 21
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 22
  • Hypovolemia (Hypovolaemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 23
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 25
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 27
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 28

List of Figures

List of Figures

  • Hypovolemia (Hypovolaemia) Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
  • Hypovolemia (Hypovolaemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Hypovolemia (Hypovolaemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017* 9
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 10
  • Proportion of Hypovolemia (Hypovolaemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 13
  • Hypovolemia (Hypovolaemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
  • Hypovolemia (Hypovolaemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 15
  • Proportion of Hypovolemia (Hypovolaemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 16
  • Hypovolemia (Hypovolaemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 17
  • Hypovolemia (Hypovolaemia) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 18
  • Hypovolemia (Hypovolaemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 19
  • Hypovolemia (Hypovolaemia) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 20
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 21
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 22
  • Hypovolemia (Hypovolaemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 23
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 24
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 26
  • Hypovolemia (Hypovolaemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 28
  • GlobalData Methodology 46
Back to Top